BioCryst/$BCRX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About BioCryst
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
- Ticker
- $BCRX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 435
- Headquarters
- Durham, United States
- Website
- www.biocryst.com
BioCryst Metrics
BasicAdvanced
$1.9B
-
-$1.49
0.51
-
Price and volume
Market cap
$1.9B
Beta
0.51
52-week high
$11.22
52-week low
$6.23
Average daily volume
5.2M
Financial strength
Current ratio
2.712
Quick ratio
2.537
Long term debt to equity
-1.965
Total debt to equity
-2.084
Interest coverage (TTM)
6.12%
Profitability
EBITDA (TTM)
473.968
Gross margin (TTM)
78.12%
Net profit margin (TTM)
-37.41%
Operating margin (TTM)
48.91%
Effective tax rate (TTM)
-1.39%
Revenue per employee (TTM)
$2,210,000
Management effectiveness
Return on assets (TTM)
56.48%
Return on equity (TTM)
91.60%
Valuation
Price to revenue (TTM)
1.879
Price to book
-4.83
Price to tangible book (TTM)
-4.83
Price to free cash flow (TTM)
4.938
Free cash flow yield (TTM)
20.25%
Free cash flow per share (TTM)
1.519
Growth
Revenue change (TTM)
60.30%
Earnings per share change (TTM)
3,194.70%
3-year revenue growth (CAGR)
44.67%
10-year revenue growth (CAGR)
45.92%
3-year earnings per share growth (CAGR)
6.01%
10-year earnings per share growth (CAGR)
4.80%
What the Analysts think about BioCryst
Analyst ratings (Buy, Hold, Sell) for BioCryst stock.
Analyst projections of the future price of BioCryst stock.
Bulls say / Bears say
ORLADEYO remains a growth engine: comparable third-quarter sales rose 20% year on year, and oral pellets extend the treatment to children while giving older patients another formulation choice. The FDA approved the pellets for patients aged 12 and above in October. (BioCryst Pharmaceuticals)
BioCryst is showing operating leverage, with third-quarter operating profit rising to $53.3 million from $29.6 million a year earlier. It also cut its 2026 operating-expense outlook and expects the Birmingham closure to deliver $30 million to $35 million in annual savings once fully realised. (BioCryst Pharmaceuticals)
The pipeline offers a possible second growth driver: navenibart’s pivotal HAE trial is fully enrolled, with results expected in the third quarter of 2027 and dosing planned every three or six months. BioCryst also expects initial patient data this year from its early-stage Netherton syndrome candidate, BCX17725. (BioCryst Pharmaceuticals)
A stronger oral rival could erode ORLADEYO’s advantage: Pharvaris reported Phase 3 results for deucrictibant showing an 83% reduction in HAE attacks versus placebo, and RBC cut its BioCryst rating while estimating ORLADEYO sales could eventually fall to $400 million–$450 million. (Yahoo Finance)
Third-quarter ORLADEYO revenue got a one-off boost from CareMed’s initial inventory build, which management estimated at the upper teens of millions of dollars. The company kept its ORLADEYO sales guidance unchanged, so reported growth may overstate the underlying run rate during the pharmacy transition. (The Motley Fool)
BioCryst’s financing obligations are substantial: at September 30 it had $400 million of secured term loans and $426.8 million of royalty financing obligations, against $376.4 million in cash and investments. That debt and royalty burden may limit flexibility if sales weaken or pipeline investment needs rise. (StockTitan)
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2026.
BioCryst Financial Performance
Revenues and expenses
BioCryst Earnings Performance
Company profitability
Upcoming events
No upcoming events
BioCryst News
AllArticlesVideos
Funds containing BioCryst
Fund name | Fund size | $BCRX weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.6B | 0.19% |
iShares Healthcare Innovation£DRDR | $1.6B | 0.19% |
iShares Healthcare Innovation€2B78 | $1.6B | 0.19% |
iShares Nasdaq US Biotechnology$BTEC | $1.3B | 0.12% |
iShares Nasdaq US Biotechnology£BTEK | $1.3B | 0.12% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.


